Feb 09, 2026 7:00am EST Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Feb 05, 2026 7:00am EST Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
Jan 20, 2026 7:00am EST Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
Nov 26, 2025 7:00am EST Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Nov 24, 2025 7:00am EST Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
Nov 20, 2025 7:00am EST Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
Nov 18, 2025 7:00am EST Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
